An oral drug has shown promise for treating metabolic syndrome in mouse models by selectively blocking the production of free radicals in the mitochondria, a research group has found. The study, carried out by a group led by Martin Brand, Professor Emeritus at the Buck Institute for Research on Aging, could lead to treatments that tackle the underlying causes of metabolic syndrome and multiple other conditions linked to aging.